CA3029003C - Associations medicamenteuses pour le traitement du cancer - Google Patents

Associations medicamenteuses pour le traitement du cancer

Info

Publication number
CA3029003C
CA3029003C CA3029003A CA3029003A CA3029003C CA 3029003 C CA3029003 C CA 3029003C CA 3029003 A CA3029003 A CA 3029003A CA 3029003 A CA3029003 A CA 3029003A CA 3029003 C CA3029003 C CA 3029003C
Authority
CA
Canada
Prior art keywords
ror
antibody
ibrutinib
antagonist
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3029003A
Other languages
English (en)
Other versions
CA3029003A1 (fr
Inventor
Thomas J. Kipps
Liguang Chen
Bing Cui
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Priority claimed from PCT/US2017/039536 external-priority patent/WO2018005519A2/fr
Publication of CA3029003A1 publication Critical patent/CA3029003A1/fr
Application granted granted Critical
Publication of CA3029003C publication Critical patent/CA3029003C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

La présente invention concerne, entre autres, des compositions et des méthodes pour le traitement du cancer.<i /> Lesdites méthodes consistent à administrer, à un sujet qui en a besoin, une quantité thérapeutiquement efficace d'un antagoniste de la tyrosine kinase de Bruton (BTK) et d'un antagoniste de ROR-1. L'invention concerne en outre des compositions pharmaceutiques comprenant un antagoniste de BTK, un antagoniste de ROR-1 et un excipient pharmaceutiquement acceptable. Dans certains modes de réalisation, l'antagoniste de BTK est l'ibrutinib et l'antagoniste de ROR-1 est le cirmtuzumab.
CA3029003A 2016-06-27 2017-06-27 Associations medicamenteuses pour le traitement du cancer Active CA3029003C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662355171P 2016-06-27 2016-06-27
US62/355,171 2016-06-27
PCT/US2017/039536 WO2018005519A2 (fr) 2016-06-27 2017-06-27 Associations médicamenteuses pour le traitement du cancer

Publications (2)

Publication Number Publication Date
CA3029003A1 CA3029003A1 (fr) 2018-01-04
CA3029003C true CA3029003C (fr) 2025-09-23

Family

ID=

Similar Documents

Publication Publication Date Title
US20240115700A1 (en) Cancer treatment combinations
US12023337B2 (en) Methods of treating cancer
US20190022096A1 (en) Methods of treating cancer
AU2016361427A1 (en) Platinum anticancer agents
WO2018089967A1 (fr) Inhibiteurs de l&#39;invasion, de la prise et/ou de la métastase du cancer
US20230066830A1 (en) Methods and compositions for inducing apoptosis in cancer stem cells
EP4065112A2 (fr) Inhibiteurs de taspase1 et leurs utilisations
CA3029003C (fr) Associations medicamenteuses pour le traitement du cancer
HK1263152A1 (en) Ciforadent alone or in combination with atezolizumab for use in treating cancer
HK1263152B (en) Ciforadent alone or in combination with atezolizumab for use in treating cancer
HK40010265A (en) Cancer treatment combinations
NZ743653A (en) Methods of treating cancer